Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.67 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | APLNR | P35414 | 4/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL28264908 | 0.90 | GNRHR (0.78) | ABCC2GNRHRPTGS1APLNR | |
| Leuprolide SCHEMBL570851 | 0.88 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.88 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.88 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL177978 | 0.88 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3915060 | 0.88 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL7751433 | 0.87 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 0.87 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL21540132 | 0.87 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 0.87 | GNRHR (0.86) | ABCC2GNRHRPTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079472-A1 | Methods for treating angiogenesis | ANGIOSYN, INC. | 2006-04-13 | — | — | US | claimed |
| CN-115461054-A | Elongation factor 1-alpha inhibitor and application thereof | 加利福尼亚大学董事会 | 2022-12-09 | — | — | CN | disclosed |
| CN-113543800-A | DNA monoclonal antibodies targeting PD-1 for treatment and prevention of cancer | 威斯塔解剖学和生物学研究所 | 2021-10-22 | — | — | CN | disclosed |
| EP-3381945-B1 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 | AMGEN FREMONT INC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3381945-A1 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 | Amgen Fremont Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2960253-B1 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 | AMGEN FREMONT INC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20160361337-A1 | FORMULATIONS OF ACADESINE | MERCK SHARP & DOHME CORP. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160213737-A1 | Methods and Compositions for Treating Conditions | NEOPRO LABS, LLC | 2016-07-28 | — | — | US | disclosed |
| EP-2960253-A1 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 | Amgen Fremont Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9221915-B2 | Human monoclonal antibodies to activin receptor-like kinase-1 | PFIZER INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20060078553-A1 | Diverse multi-unit complexes including a tRNA synthetase fragment | ANGIOSYN, INC. | 2006-04-13 | — | — | US | disclosed |
| WO-2006016217-A1 | tRNA SYNTHETASE FRAGMENTS | ANGIOSYN, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060024288-A1 | tRNA synthetase fragments | PFIZER INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060024286-A1 | Variants of tRNA synthetase fragments and uses thereof | ANGIOSYN, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060024287-A1 | Compositions and methods for modulating angiogenesis | ANGIOSYN, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060003933-A1 | Compositions and methods for treatment of neovascular diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | disclosed |
| WO-2005117954-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEOVASCULAR DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005056754-A2 | COMPOSITIONS AND METHODS TO REDUCE MUTAGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-06-23 | — | — | WO | disclosed |
| US-6613753-B2 | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation | SUPERGEN, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020114809-A1 | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation | ASTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361337-A1 | FORMULATIONS OF ACADESINE | ADORA1, TNNC1, PDF | GNRHR 3276/4885ABCC2 1413/4885PTGS1 424/4885 |
| US-20060003933-A1 | Compositions and methods for treatment of neovascular diseases | TEK, KDR, WARS1 | GNRHR 1770/4885ABCC2 3928/4885PTGS1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.